Search clinical trials for: bortezomib, tositumomab

Total 975 results

Weill Medical College of Cornell University
GlaxoSmithKline; Millennium Pharmaceuticals, Inc.

Completed

Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy

Non-Hodgkin's Lymphoma

United States
Rush University Medical Center
GlaxoSmithKline; Millennium Pharmaceuticals, Inc.

Terminated

A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma

Follicular Lymphoma

United States
GlaxoSmithKline

Completed

Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP

Lymphoma, Non-Hodgkin
Gustave Roussy, Cancer Campus, Grand Paris

Terminated

A Phase II Study of Velcade® in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer

STAGE IIIB OR IV NON-SMALL CELL LUNG CANCER

France
GlaxoSmithKline

Completed

Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin

Canada
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission

Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia | Lymphoid Leukemia in Remission

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
GlaxoSmithKline

Completed

Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma

Hodgkin's Disease

United States
University of Michigan Rogel Cancer Center
GlaxoSmithKline

Active, not recruiting

Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma

Multiple Myeloma

United States
GlaxoSmithKline

Completed

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma

Lymphoma, Mantle-Cell
GlaxoSmithKline

Completed

Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies (RIT-II-001)

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab

Non-Hodgkin's Lymphoma

United States
GlaxoSmithKline

Withdrawn

A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Small Cleaved-Cell, Follicular | Lymphoma, Large-Cell, Follicular

United States
University of Nebraska
National Cancer Institute (NCI); Coulter Pharmaceutical, Inc.

Terminated

Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States
GlaxoSmithKline

Completed

Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma.

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma

Lymphoma, Non-Hodgkin

United States, France, United Kingdom
GlaxoSmithKline

Completed

Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin
University of Florida
GlaxoSmithKline

Terminated

Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar

Follicular Lymphoma | Non-Hodgkin's Lymphoma

United States
University Hospital, Toulouse
Dana-Farber Cancer Institute; Celgene Corporation; Janssen-Cilag Ltd.

Completed

Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years (IFM/DFCI2009)

Myeloma

France
National Heart, Lung, and Blood Institute (NHLBI)
National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials...

Completed

Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401)

Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Lymphoma, Large-Cell, Immunoblastic

United States
University of Pennsylvania
GlaxoSmithKline

Completed

Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant

B-cell Lymphoma | Non-Hodgkin's Lymphoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma

United States
GlaxoSmithKline

Completed

Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin
Corixa Corporation

Unknown

A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States
The First Affiliated Hospital of Soochow University

Unknown

Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China (MM)

Multiple Myeloma Proved by Laboratory Tests

China
Baylor College of Medicine
Millennium Pharmaceuticals, Inc.

Completed

PS-341 Followed by Removal of Prostate for Those With Prostate Cancer

Prostate Neoplasms

United States
NCIC Clinical Trials Group

Completed

Bortezomib in Treating Patients With Mantle Cell Lymphoma

Lymphoma

Canada
University Hospital, Clermont-Ferrand
Laboratoires Takeda

Unknown

Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma Multiple (SENSIB)

Multiple Myeloma | Adult | Bortezomib Regimen

France
Janssen-Cilag International NV

Completed

Velcade Consolidation Bone Study

Multiple Myeloma

Turkey, Greece, Czech Republic, Austria, Germany, Sweden, United Kingdom, Denmark
University Health Network, Toronto
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter

United States, Canada
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

Lung Cancer

Canada, United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

PS-341 in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy

Lymphoma

United States
NYU Langone Health
National Cancer Institute (NCI)

Completed

PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma

Lymphoma | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer

United States
Nordic Myeloma Study Group
Janssen-Cilag Ltd.

Completed

Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients

Multiple Myeloma

Norway, Sweden, Denmark, Finland, Iceland
Nantes University Hospital

Completed

Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma

Multiple Myeloma

France
Millennium Pharmaceuticals, Inc.

Completed

Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability

Multiple Myeloma

United States
Jonsson Comprehensive Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Jonsson Comprehensive Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Bortezomib in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

United States
University of Rochester

Completed

Bortezomib in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Janssen Korea, Ltd., Korea

Completed

Quality of Life in Multiple Myeloma Patients Treated With Bortezomib

Multiple Myeloma
NCIC Clinical Trials Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group

Completed

Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

Canada, United States
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors

Islet Cell Tumor | Gastrointestinal Carcinoid Tumor

United States

3

Subscribe